Literature DB >> 7691480

Clinical features of Pseudomonas cepacia pneumonia in an epidemic among immunocompromised patients.

Y Yamagishi1, J Fujita, K Takigawa, K Negayama, T Nakazawa, J Takahara.   

Abstract

Between January 1990 and August 1991, there were 37 patients admitted to our Department of Internal Medicine with hematologic malignancies or solid tumors who showed colonization of the respiratory tract with Pseudomonas cepacia. Extensive surveillance cultures of the environmental surfaces and respiratory equipment of the hospital revealed that all nebulizing devices were contaminated with P cepacia. To characterize this outbreak, we retrospectively reviewed the medical records of 37 patients colonized with this organism. All had used nebulizers to deliver aerosols containing polymyxin B and amphotericin B as prophylaxis against infection. Sixteen of these 37 patients developed pneumonia, which was caused in 14 by P cepacia. The majority of the 14 patients showed lobular infiltrates on chest x-ray films. Cavity formation and pleural effusion were observed in 4 of the 14 (29 percent). All strains of P cepacia were resistant to piperacillin, cefotiam, sulbactam/cefoperazone, moxalactam (latamoxef), cefuzonam, amikacin, tobramycin, ofloxacin, imipenem, and carumonam. Ceftazidime was effective against 84.7 percent of the strains, while minocycline was effective against 63.5 percent of the strains. This appears to be the first report to describe the clinical features of an epidemic of nosocomial P cepacia pneumonia in immunocompromised patients.

Entities:  

Mesh:

Year:  1993        PMID: 7691480     DOI: 10.1378/chest.103.6.1706

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

Review 1.  Should patients with cystic fibrosis infected with Burkholderia cepacia undergo lung transplantation?

Authors:  A K Webb; J Egan
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

2.  Nebulised antibiotics for adults with cystic fibrosis.

Authors:  A K Webb; M E Dodd
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

3.  The dsbB gene product is required for protease production by Burkholderia cepacia.

Authors:  M Abe; T Nakazawa
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis.

Authors:  G R Hutchinson; S Parker; J A Pryor; F Duncan-Skingle; P N Hoffman; M E Hodson; M E Kaufmann; T L Pitt
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Six-year molecular analysis of Burkholderia cepacia complex isolates among cystic fibrosis patients at a referral center for lung transplantation.

Authors:  David G Heath; Kathy Hohneker; Charlene Carriker; Kelly Smith; Jonathan Routh; John J LiPuma; Robert M Aris; David Weber; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

Review 6.  Management of cystic fibrosis before and after lung transplantation.

Authors:  J J Egan; A A Woodcock; A K Webb
Journal:  J R Soc Med       Date:  1997       Impact factor: 18.000

Review 7.  Outbreaks of healthcare-associated infections linked to water-containing hospital equipment: a literature review.

Authors:  Wing-Kee Yiek; Olga Coenen; Mayke Nillesen; Jakko van Ingen; Edmée Bowles; Alma Tostmann
Journal:  Antimicrob Resist Infect Control       Date:  2021-05-10       Impact factor: 4.887

8.  Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis.

Authors:  M McCloskey; J McCaughan; A O Redmond; J S Elborn
Journal:  Ir J Med Sci       Date:  2001 Jan-Mar       Impact factor: 2.089

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.